ALISKIREN HEMIFUMARATE

Post-LOE

aliskiren

ANDAORALTABLET
Approved
Mar 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla…

Clinical Trials (5)

NCT01922141Phase 4Withdrawn

Aliskiren Study of Safety and Efficacy in Senior Hypertensives

Started May 2015
0
Hypertension
NCT01570686Phase 4Completed

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Started Apr 2012
589 enrolled
Hypertension
NCT01480791Phase 2Withdrawn

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Started Jan 2012
0
HypertensionDiabetes
NCT01472796Phase 4Unknown

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension

Started Jul 2011
92 enrolled
Hypertension
NCT01349114Phase 4Terminated

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Started Jun 2011
21 enrolled
DiabetesPre-hypertensionHypertension